Estimation of bovine leukemia virus (BLV) proviral load harbored by lymphocyte subpopulations in BLV-infected cattle at the subclinical stage of enzootic bovine leucosis using BLV-CoCoMo-qPCR
- Carlos Javier Panei†1, 2,
- Shin-nosuke Takeshima†1,
- Takashi Omori3,
- Tetsuo Nunoya3,
- William C Davis4,
- Hiroshi Ishizaki5,
- Kazuhiro Matoba5 and
- Yoko Aida1Email author
© Panei et al.; licensee BioMed Central Ltd. 2013
Received: 22 January 2013
Accepted: 17 April 2013
Published: 4 May 2013
Bovine leukemia virus (BLV) is associated with enzootic bovine leukosis (EBL), which is the most common neoplastic disease of cattle. BLV infection may remain clinically silent at the aleukemic (AL) stage, cause persistent lymphocytosis (PL), or, more rarely, B cell lymphoma. BLV has been identified in B cells, CD2+ T cells, CD3+ T cells, CD4+ T cells, CD8+ T cells, γ/δ T cells, monocytes, and granulocytes in infected cattle that do not have tumors, although the most consistently infected cell is the CD5+ B cell. The mechanism by which BLV causes uncontrolled CD5+ B cell proliferation is unknown. Recently, we developed a new quantitative real-time polymerase chain reaction (PCR) method, BLV-CoCoMo-qPCR, which enabled us to demonstrate that the proviral load correlates not only with BLV infection, as assessed by syncytium formation, but also with BLV disease progression. The present study reports the distribution of BLV provirus in peripheral blood mononuclear cell subpopulations isolated from BLV-infected cows at the subclinical stage of EBL as examined by cell sorting and BLV-CoCoMo-qPCR.
Phenotypic characterization of five BLV-infected but clinically normal cattle with a proviral load of > 100 copies per 1 × 105 cells identified a high percentage of CD5+ IgM+ cells (but not CD5- IgM+ B cells, CD4+ T cells, or CD8+T cells). These lymphocyte subpopulations were purified from three out of five cattle by cell sorting or using magnetic beads, and the BLV proviral load was estimated using BLV-CoCoMo-qPCR. The CD5+ IgM+ B cell population in all animals harbored a higher BLV proviral load than the other cell populations. The copy number of proviruses infecting CD5- IgM+ B cells, CD4+ cells, and CD8+ T cells (per 1 ml of blood) was 1/34 to 1/4, 1/22 to 1/3, and 1/31 to 1/3, respectively, compared with that in CD5+ IgM+ B cells. Moreover, the BLV provirus remained integrated into the genomic DNA of CD5+ IgM+ B cells, CD5- IgM+ B cells, CD4+ T cells, and CD8+ T cells, even in BLV-infected cattle with a proviral load of <100 copies per 105 cells.
The results of the recent study showed that, although CD5+ IgM+ B cells were the main cell type targeted in BLV-infected but clinically normal cattle, CD5- IgM+ B cells, CD4+ cells, and CD8+ T cells were infected to a greater extent than previously thought.
KeywordsBovine leukemia virus (BLV) Proviral load BLV-CoCoMo-qPCR CD5+IgM+ B cell Cell sorting Flow cytometry
Bovine leukemia virus (BLV), a close relative of human T cell leukemia virus types-1 and -2 (HTLV-1 and HTLV-2), is the etiologic agent responsible for enzootic bovine leukosis (EBL), which is the most common neoplastic disease of cattle. Infection by BLV may remain clinically silent at the aleukemic (AL) stage. However, in 30% of infected cattle the infection may manifest as persistent lymphocytosis (PL; a condition characterized by an increase in the number of B lymphocytes), and in around 1–5% of cases it may manifest as B cell lymphoma after a long period of latency . Sheep experimentally inoculated with BLV develop B cell tumors at a higher frequency than naturally infected cattle, and the period of latency is shorter [2, 3].
In infected cattle with no evident tumor, BLV has been identified in B cells, CD2+ T cells, CD3+ T cells, CD4+ T cells, CD8+ T cells, γ/δ T cells, monocytes and granulocytes [4–6]. By contrast, the increase in lymphocyte numbers observed in cows with PL is entirely attributable to the expansion of the CD5- and CD5+ B cell subpopulations, indicating that CD5- and CD5+ B cells are the only mononuclear cells within the peripheral blood that are significantly infected with BLV . Furthermore, the most consistent tumor cell phenotypes isolated from cattle with EBL are CD5+, CD6–, B1 low+, B2+, major histocompatibility complex class II+, and either sIgM+ or sIgM–; this indicates the involvement of the CD5+ B cell sub population rather than the CD5-B cell sub population. However, the mechanism by which BLV induces uncontrolled CD5+ B cell proliferation is unknown. It is interesting to note that in sheep, transformed B cells show a CD5- phenotype . Indeed, we previously showed that the extended survival of peripheral blood mononuclear cells (PBMCs) ex vivo was mainly due to the presence of BLV-expressing CD5– B cells, indicating that sheep CD5– B cells may be particularly susceptibility to the transforming effects of BLV . This increase in the survival of BLV-expressing sheep PBMCs was also associated with an increase in the expression of mRNA for bcl-xl, but not that for bcl-2 or bax. However, the mechanism by which BLV protects ex vivo cultured cells against apoptosis is unknown.
After infecting cattle, BLV enters a period of latency, during which expression is blocked at the transcriptional level [10–12]. BLV-infected cattle retain at least one copy of the full-length proviral genome throughout the course of the disease , suggesting that the BLV provirus remains integrated within the cellular genome , even in the absence of detectable BLV antibodies . Therefore, diagnostic BLV polymerase chain reaction (PCR) techniques, which detect the integrated BLV proviral genome within the host genome, are now commonly used to detect BLV infection in addition to routine diagnostic tests such as agar gel immunodiffusion and enzyme-linked immunosorbent assays (ELISAs) [13, 15–18]. Recently, we developed a new quantitative real-time PCR method using Coordination of Common Motifs (CoCoMo) primers to measure the proviral load of both known and novel BLV variants in BLV-infected animals [14, 19]. The assay was highly effective in detecting BLV in cattle from a number of international locations. The BLV-CoCoMo-qPCR technique amplifies a single-copy host gene, the bovine leukocyte antigen (BoLA)-DRA gene, in parallel with viral genomic DNA, which effectively normalizes the level of viral genomic DNA. Thus, we were able to show that the proviral load correlates not only with the level of BLV propagation, as assessed by syncytium formation, but also with BLV disease progression.
While the primary cellular target of BLV is B cells, recent studies suggest that monocytes, granulocytes, CD2+ T cells, CD3+ T cells, CD4+ T cells, CD8+ T cells and γ/δ T cells are also targets [4–6, 20]. However, because Mirsky et al. , fractionated B cells into the CD5+ IgM+ B cells and CD5- IgM+ B cell subpopulations, but did not fractionate CD2+ T cells into the CD4+ and CD8+ T cell subpopulations. In contrast, Wu et al.  isolated the CD4+ and CD8+ T cell subpopulations, but did not fractionate B cells into the CD5+ IgM+ B cells and CD5- IgM+ B cell subpopulations. It remains to be clarified the variations of the BLV proviral load among CD5+ IgM+ B cells, CD5- IgM+ B cells, CD4+ T cells, and CD8+ T cells in the same experiment. Therefore, to clarify whether these subpopulations are susceptible to BLV infection, we obtained PBMCs from cattle naturally infected with BLV and isolated CD5+ IgM+ B cells, CD5- IgM+ B cells, CD4+ T cells, and CD8+ T cells by flow cytometry or using magnetic beads. We then estimated the BLV proviral load using the BLV-CoCoMo-qPCR technique. The results show that CD5+ IgM+ B cells, CD5- IgM+ B cells, CD4+ T cells, and CD8+ T cells are all primary targets for BLV.
Animals, blood samples, sera, and DNA extraction
Outline of examined BLV-infected but clinically normal cattle
Lymphocyte (/μl) (%)
(Copies/1 × 105cells)
(Number/5 × 106cells)
BLV-free normal cattle
1) Cattle with < 100 proviral load
2) Cattle with > 100 proviral load
Genomic DNA was isolated from EDTA-treated whole blood samples using the Wizard Genomic DNA Purification Kit (Promega Corporation, Tokyo, Japan) and subsequently used for PCR.
Measurement of the BLV proviral load using BLV-CoCoMo-qPCR
The BLV proviral load was measured using BLV-CoCoMo-qPCR as previously described . Briefly, the BLV long terminal repeat (LTR) region was amplified using the degenerate primer pair: CoCoMo 6 and CoCoMo 81. FAM BLV was used as a probe. The BoLA-DRA gene (internal control) was amplified using the primer pair, DRA643 and DRA734. VIC-DRA was used as a probe.
An anti-BLV antibody ELISA kit (JNC Inc., Tokyo, Japan) was used to detect anti-BLV antibodies according to the manufacturer’s instructions.
Syncytium formation assay
To determine the presence of BLV in the cattle, PBMCs (5 × 106 cells/4 ml) were mixed with CC81 cells (cat cells transformed with mouse sarcoma virus;1 × 105 cells/4 ml) and 4 μg/ml polybrene (Sigma, St. Louis, MO) in 6 cm diameter culture dishes and used in a syncytium formation assay [19, 24]. Syncytia were counted under a light microscope after staining with May-Grunwald Giemsa. CC81 cells were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin (100 μg/ml).
Monoclonal antibodies (MAbs) and detection of surface markers by flow cytometry
PBMCs were labeled using optimal concentrations of the following MAbs: CACT105A (mouse anti-bovine CD5; VMRD Inc., Pullman, WA); BAQ44A (mouse anti-bovine IgM; VMRD Inc.); ILA11A (mouse anti-bovine CD4; VMRD Inc.); or 7C2B (mouse anti-bovine CD8; VMRD Inc.). The cells were then stained with the following secondary fluorophore-labeled MAbs: allophycocyanin (APC)-conjugated rat anti-mouse IgG1 (BD Pharmingen, Tokyo, Japan) to detect CACT105A-positive cells; phycoerythrin (PE)-conjugated goat anti-mouse IgM (CALTAG Laboratories, Carlsbad, CA) to detect BAQ44A-positive cells; or PE-conjugated goat anti-mouse IgG2a (Invitrogen, Camarillo, BD Japan) to detect ILA11A- or 7C2B-positive cells. After staining, cells were analyzed using a FACSCalibur™ flow cytometer (BD Japan, Tokyo, Japan) and the data were analyzed using FCS Express (Ver. 3; De Novo Software, Los Angeles, CA). Cells stained with normal mouse serum and appropriate secondary antibodies were used as a negative control.
CD5+ IgM+ cells and CD5+ IgM- cells were separated from PBMCs using a BD FACSAria™ cell sorter (BD Japan). The purity of the sorted populations was assessed using the same cytometer.
CD4+ and CD8+ cells were purified using the MACS® System (Miltenyi Biotech Inc, Auburn, CA). In brief, PBMCs were stained with ILA11A MAb (mouse anti-bovine CD4; VMRD Inc.) or 7C2B MAb(mouse anti-bovine CD8; VMRD Inc.) and captured by an anti-mouse IgG MAb conjugated to magnetic beads. Magnetic bead-bound cells were separated on an LS column. The purity of the CD4+ and CD8+ cell populations was calculated by indirect immunofluorescence analysis.
To estimate the BLV proviral load in cattle at the clinically normal stage of BLV infection, we obtained blood samples from eight Holstein cows and one Japanese black cow and analyzed them by BLV-CoCoMo-qPCR. Two cattle were BLV-negative (N790 and N791) and seven were BLV-positive (N818, N789, N787, N733, N823, N788 and O10) (Table 1). The same results were obtained using the anti-BLV ELISA. The seven BLV-infected cattle were then classified according to the EC-leukosis key : Six cattle were categorized as BLV-infected but clinically and hematologically normal cattle, and one was categorized as BLV-infected but clinically normal cattle with PL.
The BLV proviral load in the nucleated cells isolated from blood samples taken from the nine cattle was examined using BLV-CoCoMo-qPCR, and the infection capacity of BLV was assessed using the syncytium assay (Table 1). The proviral load correlated strongly with the syncytium count. For example, the proviral load in animals N787, N733, N823, N788 and O10 ranged from 294 to 18,094 copies per 105 cells, and syncytium numbers ranged from 250 to 17,500 per 5 × 106 PBMCs. Furthermore, animals N818 and N789, which had low proviral loads (8 and 26 copies per 105 PBMCs, respectively) also had very low syncytium counts (0 and 1 per 5 × 106 PBMCs, respectively), meaning that the sensitivity of CoCoMo-qPCR for detecting BLV infection was greater than that of the syncytium assay.
Proviral load in the different lymphocyte subpopulations isolated from selected BLV-infected but clinically normal cattle.
1) BLV-infected cattle (proviral load > 100 copies/105 cells)
2) BLV-infected cattle (proviral load < 100 copies/105 cells)
Estimation of the proviral copy number (per 1 mL peripheral blood a ) in each lymphocyte subpopulation using BLV-CoCoMo-qPCR
Proviral load (Copies/105cells)
Proviral copy number/ml of blood in each of the lymphocyte subpopulations
1) BLV-infected cattle ( proviral load > 100 copies/105 cells)
2) BLV-infected cattle (proviral load < 100 copies/105 cells)
BLV proviruses were mainly present in CD5+ IgM+ B cells isolated from the three BLV-infected cattle with a proviral load >100 copies per 105 cells (N733, N788 and O10), followed by CD4+ T cells; however, the proviral loads in CD4+ cells were around 3- to 22-times lower than those in CD5+ IgM+ B cells. BLV also infected CD8+ T cells and CD5- IgM + B cells, although the proviral loads in each of these subpopulations were different in each animal. In addition, in the case of animal with low proviral load N818 (proviral load <100 copies per 105 cells), the actual proviral copy number in CD5- IgM+ B cells per ml blood was greater than that in CD5+ IgM+ B cells, CD4+ T cells, or CD8+ T cells.
The present study showed that the proviral load in CD5+ IgM+ B cells (which are the primary target cells for BLV infection) was higher than that in CD4+ T cells, CD8+ T cells, or CD5- IgM+ B cells, both in terms of proviral load per 105 cells (Table 2) and in terms of actual copy number per ml of blood (Table 3) in all cattle with a proviral load >100 copies per 105 cells. Interestingly, we showed that the second most commonly infected cell in these animals was the CD4+ T cell. Furthermore, we showed that BLV appears to infect both CD8+ T cells and CD5- IgM + B cells to a greater extent than was reported in a previous study . The current data support the studies by Williams et al. , Stott et al. , and Wu et al.  which reported that some T cells can be infected by BLV. However, in contrast to our results showing that CD4+ T cells are the second most common target for BLV infection in cattle, Schwartz et al.  reported that, although B cells, CD8+ T cells, monocytes, and granulocytes were infected by BLV, CD4+ T cells were not. Moreover, Mirsky et al, used flow cytometry and single-cell PCR to show that CD5+ IgM+ and CD5- IgM+ B cells were the only PBMCs infected with BLV in seropositive cows, either with or without PL . They also suggested that peripheral CD2+ T cells, γ/δ T cells, and monocytes are not a major reservoir for BLV infection. By contrast, the present study showed that the BLV provirus remains integrated in the DNA of CD5+ IgM+ B cells, CD5- IgM+ B cells, CD4+ T cells, and CD8+ T cells, even in animals with a proviral load <100 copies per 105 cells of which lower than the limitation of sensitivity of CoCoMo-qPCR. Thus, we were able to use cell sorting and BLV-CoCoMo-qPCR techniques to detect the BLV provirus in all the lymphocyte subpopulations isolated from BLV-infected, clinically normal, cattle with and without PL. Taken together, the results show that CD5+ IgM+ B cells, CD5- IgM+ B cells, CD4+ T cells, and CD8+ T cells are all primary targets for BLV.
Thus, it appears that BLV can infect a broad spectrum of cells, although its receptor(s) remains unknown. A previous report used the BLV envelope (ENV) receptor binding domain showed that BLV receptor molecules are expressed by pro/pre B cells (but not by mature/arrested B cells), by activated B and T cells (but not by arrested B and T cells), by human thymus cells induced by IL-7, and by proliferating lymphocytes . CD4, CD8, and CD5- IgM+ B cells proliferate in an antigen-specific manner; however, CD5+ IgM+ B cells can proliferate in the absence of antigen. Therefore, CD5+ IgM+ B cells may constitutively express receptors for BLV, which may explain why CD5+ IgM+ B cells harbor a high viral load.
One advantage of measuring proviral loads is that such measurements can be used to follow the dynamics of BLV-infected cells in vivo. Mirsky and coworkers  reported that the infection rate was approximately 40-fold higher for CD5+ B cells than for CD2+ T cells (121 ± 244 for CD5+ B cells and 3 ± 6 for CD2+ T cells), suggesting that B cells are the only PBMCs significantly infected by BLV. However, they did not subfractionate CD2+ T cells to CD4+ and CD8+ cells. Our result showed that CD4+ T cells harbored higher proviral copy numbers than CD8+ and CD5-IgM+ B cells in all three cattle with a proviral load >100 copies per 105 cells. In addition, the data showed that the fold difference in the proviral load in CD5+ IgM+ B cells and T cells (CD4+ T cells + CD8+ T cells) ranged from 1.5 (360,816/(133,782 + 111,587) copies per ml) in N788 to 13 (268,914/(11,980 + 8,811) copies per ml) in N733. This indicates that, in addition to CD5+ IgM+ B cells, T cells are also infected with BLV. Moreover, the syncytium assay were used for comparing with PBMC and purified CD4+ T cell and rate of the number of syncytium formation with 5 × 106 of PBMC per with CD4+ T cells were almost 1.6 (data not shown). This result suggests that CD4+ T cells could be infected by BLV, and that BLV-infected CD4+T cells may be the source of infectious BLV-infected cells that can then infect other cells. Both the previous studies and the present study examined the proviral load in cell populations derived from peripheral blood. It is still not known which peripheral blood or organs maintain BLV proliferation. To investigate the mechanism(s) underlying BLV proliferation in vivo, it will be necessary to analyze the proviral load in key organs and in peripheral blood.
To clarify which subpopulations of lymphocytes were infected by BLV at subclinical stage, we used the BLV-CoCoMo-qPCR method, which enabled us to demonstrate that proviral load correlates not only with BLV infection capacity, as assessed by syncytium formation, but also with BLV disease progression. This study shows that, while CD5+ IgM+ B cells harbor the greatest BLV proviral load during the subclinical stage of EBL, CD4+ T cells and CD8+ T cells are also primary targets for BLV. Taken together, the results of this study show that the tropism of BLV is wider than previously thought.
CJ Panei (Ph.D.,D.V.M.): Visiting researcher of RIKEN and Assistant Professor of National University of La Plata. Shin-nosuke Takeshima (Ph.D.): ASI researcher of RIKEN and Associate Professor of The University of Tokyo. WC. Davis (Ph.D.,D.V.M.): Professor of Washington State University. Takashi Ohmori (Ph.D.,D.V.M.): Nippon Institute for Biological Science. Tetsuo Nunoya (Ph.D.,D.V.M.): Nippon Institute for Biological Science. Hiroshi Ishizaki (Ph.D.,D.V.M.): NARO Institute of Livestock and Grassland Sciences. Kazuhiro Matoba (M.A.): NARO Institute of Livestock and Grassland Sciences. Yoko Aida (Ph.D.,D.V.M.): Unit leader of RIKEN and Professor of The University of Tokyo.
Bovine leukemia virus
- HTLV-1 and HTLV-2:
Human T cell leukemia virus types 1 and 2
Enzootic bovine leucosis
Peripheral blood mononuclear cells
Enzyme-linked immunosorbent assay
Polymerase chain reaction
Coordination of common motifs
Bovine leukocyte antigen
We are grateful to the Support Unit for Bio-material Analysis, RIKEN BSI Research Resources Center, for help with flow cytometry. This work was supported by Grants-in-Aid for Young Scientists (B) and for Scientific Research (B) from the Japan Society for the Promotion of Science (JSPS), by RIKEN ASI Invitation Program, by A-STEP (Adaptable & Seamless Technology Transfer Program through Target-driven R&D) from Japan Science and Technology Agency (JST) and by a grant from the Program for the Promotion of Basic and Applied Research for Innovations in Bio-oriented Industry.
- Burny A, Cleuter Y, Kettmann R, Mammerickx M, Marbaix G, Portetelle D, van den Broeke A, Willems L, Thomas R: Bovine leukaemia: facts and hypotheses derived from the study of an infectious cancer. Vet Microbiol. 1988, 17 (3): 197-218. 10.1016/0378-1135(88)90066-1.PubMedView Article
- Aida Y, Miyasaka M, Okada K, Onuma M, Kogure S, Suzuki M, Minoprio P, Levy D, Ikawa Y: Further phenotypic characterization of target cells for bovine leukemia virus experimental infection in sheep. Am J Vet Res. 1989, 50 (11): 1946-1951.PubMed
- Djilali S, Parodi AL, Levy D, Cockerell GL: Development of leukemia and lymphosarcoma induced by bovine leukemia virus in sheep: a hematopathological study. Leukemia. 1987, 1 (11): 777-781.PubMed
- Stott ML, Thurmond MC, Dunn SJ, Osburn BI, Stott JL: Integrated bovine leukosis proviral DNA in T helper and T cytotoxic/suppressor lymphocytes. J Gen Virol. 1991, 72 (Pt 2): 307-315.PubMedView Article
- Mirsky ML, Olmstead CA, Da Y, Lewin HA: The prevalence of proviral bovine leukemia virus in peripheral blood mononuclear cells at two subclinical stages of infection. J Virol. 1996, 70 (4): 2178-2183.PubMedPubMed Central
- Schwartz I, Bensaid A, Polack B, Perrin B, Berthelemy M, Levy D: In vivo leukocyte tropism of bovine leukemia virus in sheep and cattle. J Virol. 1994, 68 (7): 4589-4596.PubMedPubMed Central
- Murakami K, Okada K, Ikawa Y, Aida Y: Bovine leukemia virus induces CD5- B cell lymphoma in sheep despite temporarily increasing CD5+ B cells in asymptomatic stage. Virology. 1994, 202 (1): 458-465. 10.1006/viro.1994.1362.PubMedView Article
- Takahashi M, Tajima S, Takeshima SN, Konnai S, Yin SA, Okada K, Davis WC, Aida Y: Ex vivo survival of peripheral blood mononuclear cells in sheep induced by bovine leukemia virus (BLV) mainly occurs in CD5- B cells that express BLV. Microbes Infect. 2004, 6 (6): 584-595. 10.1016/j.micinf.2004.02.014.PubMedView Article
- Takahashi M, Tajima S, Okada K, Davis WC, Aida Y: Involvement of bovine leukemia virus in induction and inhibition of apoptosis. Microbes and infection / Institut Pasteur. 2005, 7 (1): 19-28. 10.1016/j.micinf.2004.09.014.PubMedView Article
- Kettmann R, Deschamps J, Cleuter Y, Couez D, Burny A, Marbaix G: Leukemogenesis by bovine leukemia virus: proviral DNA integration and lack of RNA expression of viral long terminal repeat and 3' proximate cellular sequences. Proc Natl Acad Sci U S A. 1982, 79 (8): 2465-2469. 10.1073/pnas.79.8.2465.PubMedPubMed CentralView Article
- Lagarias DM, Radke K: Transcriptional activation of bovine leukemia virus in blood cells from experimentally infected, asymptomatic sheep with latent infections. J Virol. 1989, 63 (5): 2099-2107.PubMedPubMed Central
- Tajima S, Tsukamoto M, Aida Y: Latency of viral expression in vivo is not related to CpG methylation in the U3 region and part of the R region of the long terminal repeat of bovine leukemia virus. J Virol. 2003, 77 (7): 4423-4430. 10.1128/JVI.77.7.4423-4430.2003.PubMedPubMed CentralView Article
- Tajima S, Ikawa Y, Aida Y: Complete bovine leukemia virus (BLV) provirus is conserved in BLV-infected cattle throughout the course of B-cell lymphosarcoma development. J Virol. 1998, 72 (9): 7569-7576.PubMedPubMed Central
- Jimba M, Takeshima SN, Murakami H, Kohara J, Kobayashi N, Matsuhashi T, Ohmori T, Nunoya T, Aida Y: BLV-CoCoMo-qPCR: a useful tool for evaluating bovine leukemia virus infection status. BMC Vet Res. 2012, 8 (1): 167-10.1186/1746-6148-8-167.PubMedPubMed CentralView Article
- Lew AE, Bock RE, Molloy JB, Minchin CM, Robinson SJ, Steer P: Sensitive and specific detection of proviral bovine leukemia virus by 5' Taq nuclease PCR using a 3' minor groove binder fluorogenic probe. J Virol Methods. 2004, 115 (2): 167-175. 10.1016/j.jviromet.2003.09.029.PubMedView Article
- Monti GE, Frankena K: Survival analysis on aggregate data to assess time to sero-conversion after experimental infection with Bovine Leukemia virus. Prev Vet Med. 2005, 68 (2–4): 241-262.PubMedView Article
- Kurdi A, Blankenstein P, Marquardt O, Ebner D: [Serologic and virologic investigations on the presence of BLV infection in a dairy herd in Syria]. Berl Munch Tierarztl Wochenschr. 1999, 112 (1): 18-23.PubMed
- Zaghawa A, Beier D, Abd El-Rahim IH, Karim I, El-ballal S, Conraths FJ, Marquardt O: An outbreak of enzootic bovine leukosis in upper Egypt: clinical, laboratory and molecular-epidemiological studies. J Vet Med B Infect Dis Vet Public Health. 2002, 49 (3): 123-129. 10.1046/j.1439-0450.2002.00517.x.PubMedView Article
- Jimba M, Takeshima SN, Matoba K, Endoh D, Aida Y: BLV-CoCoMo-qPCR: Quantitation of bovine leukemia virus proviral load using the CoCoMo algorithm. Retrovirology. 2010, 7: 91-10.1186/1742-4690-7-91.PubMedPubMed CentralView Article
- Williams DL, Barta O, Amborski GF: Molecular studies of T-lymphocytes from cattle infected with bovine leukemia virus. Vet Immunol Immunopathol. 1988, 19 (3–4): 307-323.PubMedView Article
- Wu D, Murakami K, Morooka A, Jin H, Inoshima Y, Sentsui H: In vivo transcription of bovine leukemia virus and bovine immunodeficiency-like virus. Virus Res. 2003, 97 (2): 81-87. 10.1016/S0168-1702(03)00222-3.PubMedView Article
- Miyasaka M, Trnka Z: Sheep as an experimental model for immunology immunological techniques in vitro and in vivo. In Immunological Methods.Volume 3, ednth edition. Edited by Lefkovits I. ; 1985:403–423.
- Mammerickx M, Otte J, Rase F, Braibant E, Portetelle D, Burny A, Dekegel D, Ghysdael J: Large scale serological detection in Belgium of enzootic bovine leukosis. Zentralblatt fur Veterinarmedizin Reihe B Journal of veterinary medicine Series B. 1978, 25 (5): 416-424.PubMedView Article
- Tajima S, Takahashi M, Takeshima SN, Konnai S, Yin SA, Watarai S, Tanaka Y, Onuma M, Okada K, Aida Y: A mutant form of the tax protein of bovine leukemia virus (BLV), with enhanced transactivation activity, increases expression and propagation of BLV in vitro but not in vivo. J Virol. 2003, 77 (3): 1894-1903. 10.1128/JVI.77.3.1894-1903.2003.PubMedPubMed CentralView Article
- Lavanya M, Kinet S, Montel-Hagen A, Mongellaz C, Battini JL, Sitbon M, Taylor N: Cell surface expression of the bovine leukemia virus-binding receptor on B and T lymphocytes is induced by receptor engagement. J Immunol. 2008, 181 (2): 891-898.PubMedView Article